NEWS RELEASE for March 18, 2010


BIOLASE Announces Changes in Sales and Marketing Organization

IRVINE, CA (March 18, 2010) — BIOLASE Technology, Inc. (NASDAQ:BLTI), the world’s leading dental laser company, today reported operating results for the 2009 fourth quarter and fiscal year ended December 31, 2009.

Net revenue for the fourth quarter of 2009 was $10.4 million, compared to $11.6 million in the prior year quarterly period. The year-to-year change in revenue in the 2009 fourth quarter was driven by lower licensing fees and reduced purchases by distributors. This was partially offset by a 67 percent increase in consumable sales and a seven percent increase in global service revenues, driven by the Company’s initiatives to expand offerings in upgrades, accessories, and services to its existing customer base.

Gross margin as a percentage of net revenue for the 2009 fourth quarter was 42 percent, compared to 47 percent for the 2008 fourth quarter. The decrease was primarily due to lower licensing fees and a higher mix of international sales in the quarter, which have lower sales prices. Operating expenses in the 2009 fourth quarter were $5.8 million, compared to $10.3 million in the year-earlier quarterly period, which reflects a 44 percent decrease in Company expenditures.

Net loss for the 2009 fourth quarter was $1.5 million, or $0.06 loss per share, compared to a net loss of $5.3 million, or $0.22 loss per share, in the 2008 fourth quarter. Non-GAAP net loss was $888,000 or $0.04 loss per share on a non-GAAP basis for the 2009 fourth quarter compared with non-GAAP net loss of $4.3 million or $0.18 loss per share on a non-GAAP basis for the similar quarter in 2008.

Net revenue for 2009 was $43.3 million, compared to $64.6 million in the prior year. Revenues for 2009 were impacted by the adverse worldwide economic environment, the restructuring and closure of four direct international sales subsidiaries and the ramp up of new distributors in those countries, lower domestic purchases per the purchase agreement with the Company’s distribution partner, Henry Schein (NASDAQ:HSIC), and lower licensing fees and royalty income. Consumables and service revenue increased 20 percent year over year, attributed largely to the release of the Waterlase MD Turbo™ Handpiece Upgrade Kit.

Gross margin as a percentage of net revenue for 2009 was 46 percent, compared to 51 percent for 2008. The decrease was due largely to a one-time write down of inventories in the first quarter of 2009 related to the international subsidiary closures, a decrease in licensing and royalty revenues and lower volumes. Operating expenses in 2009 were $23.0 million, down from $41.4 million in the prior year. In late 2008 and continuing into 2009, the Company implemented significant cost reductions to help offset the negative impact of current economic conditions.

GAAP net loss for 2009 was $3.0 million, or $0.12 loss per share, compared to a net loss of $9.1 million, or $0.38 loss per share in the prior year period. Non-GAAP net loss was $97,000 or $0.00 loss per share on a non-GAAP basis for 2009 compared with non-GAAP net loss of $5.3 million or $0.22 loss per share on a non-GAAP basis for 2008.

BIOLASE Chief Executive Officer David M. Mulder said, “The minimum purchase agreement we signed last year with Henry Schein was a great stabilizer for the Company during the economic upheaval of 2009. While it was a very challenging year for medical capital equipment companies, we were able to bring the Company to a near break-even status on a non-GAAP basis and enjoyed the best bottom line performance in six years. More significantly, during the year we did not wait for a turnaround in the economy, but invested in growth for the future.”

Other 2009 Highlights:

    Launch of Waterlase MD Turbo™ hard and soft tissue dental laser system. This provided additional speed and addressed a historic issue slowing sales.

    FDA 510(K) clearance of the ezlase® diode laser for pain therapy relief was followed by the launch of the Diolase 10™ diode laser for therapeutic applications, including temporary pain relief. This was released in late 2009 and is the first product that is part of a long-term strategic expansion into the medical specialty markets, including sports medicine, orthopedics, physical therapy and chiropractics.

    Three regional distribution agreements were finalized in the People’s Republic of China, one of the world’s fastest growing dental markets, after approval was granted earlier in the year.

    Introduction of the Company’s new Deep Pocket Therapy with New Attachment™ using the Waterlase MD® and patented Radial Firing Perio Tips™ for a non-surgical alternative treatment for moderate to advanced periodontal disease.

    FDA 510(K) clearance of the Waterlase MD® for removing calculus in patients with periodontal disease.

    The Levin Group, a leading international dental practice consulting firm, developed an independent ROI story and practice management system for the successful integration and implementation of BIOLASE® dental lasers into everyday dental offices, which was presented at the March 2010 World Clinical Laser Institute (WCLI™) dentistry symposium and is slated for publication in a leading Dental Journal in March 2010.

    Preparation for the launch of the iLase™, which was launched February 2010 and is now being pre-sold in select approved countries. FDA approval in the United States was granted earlier this week. Shipments are expected to begin in the second quarter of 2010.

Mulder continued, “While we remain confident in the long-term outlook and the new deal structure, we expect some volatility in revenues for the first half of the year. We have agreed to accept a substantial portion of the remaining balance of the initial 14 month commitment from Henry Schein in orders placed and paid for (prepaid orders), but with delivery later in the year. This may guarantee cash flow, but will result in sales being recognized in future quarters. As a result, we believe revenues for the first quarter of 2010 will be lower than the same period in 2009. We expect the second quarter to be a strong recovery over the first quarter, but prepaid orders may continue to delay some revenue recognition.”

Mulder concluded, “Last week we amended our licensing and distribution agreement with Henry Schein. The new agreement, signed on March 9, 2010, provides monthly guaranteed minimum payments and upside opportunity to expand beyond those minimums, with strong incremental sales and margin incentives for BIOLASE to expand into more non-traditional Schein accounts. To ensure we continue to support Henry Schein and capture that additional potential, we have already started expanding our North American sales force, with a target of almost doubling the number of sales representatives. Today we appointed Wayne R. Harrison, DDS, as our new Vice President North American Dental Sales and Marketing. Before joining BIOLASE, Dr. Harrison had a career as a dentist, educator and top global luminary for Nobel Biocare. Within BIOLASE, Dr. Harrison was a top performing sales representative and then served as our best-performing Regional Sales Director, while concurrently assisting with new product development and marketing. As a team, we are establishing a strong sales and marketing infrastructure with internal management talent for the future, and doing it with dental experience that cannot be matched. With our strong partnerships, people and products, we are well positioned to grow the Company as the economic environment improves.”

Conference Call
As previously announced, the Company will host a conference call today at 11:00 a.m. Eastern Time to discuss its operating results for the fourth quarter and year ended December 31, 2009, and to answer questions. The dial-in number for the call is toll-free 1-877-941-8416 or toll/international 1-480-629-9808. The live webcast and archived replay of the call can be accessed in the Investors section of the BIOLASE website at

About BIOLASE Technology, Inc.
BIOLASE Technology, Inc. (, the world’s leading dental laser company, develops, manufactures and markets Waterlase technology and lasers and related products that advance the practice of dentistry and medicine.  The Company’s products incorporate patented and patent pending technologies designed to provide clinically superior performance with reduced pain and faster recovery times.  BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications.  Other products under development address ophthalmology, pain management and other medical and consumer markets.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions.  Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company’s actual results to differ materially from the statements contained herein, and are described in the Company’s reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

For further information, please contact: Jill Bertotti (investors) or Len Hall (media), of Allen & Caron, +1-949-474-4300.


(in thousands, except per share data)

    Three months ended December 31,           Year ended December 31,
    2009   2008       2009   2008
Products and services revenue
  $ 10,335     $ 10,760             $ 42,137     $ 61,010  
License fees and royalty income
    16       875               1,210       3,615  
Net revenue
    10,351       11,635               43,347       64,625  
Cost of revenue
    5,988       6,193               23,285       31,963  
Gross profit
    4,363       5,442               20,062       32,662  
Operating expenses
Sales and marketing
    2,995       5,768               11,041       22,040  
General and administrative
    1,832       2,366               7,835       12,006  
Engineering and development
    945       1,535               4,146       5,580  
Impairment of Intangible Asset
          232                     232  
Impairment of PP&E
          355                     355  
Patent infringement legal settlement
Total operating expenses
    5,772       10,256               23,022       41,445  
Loss from operations
    (1,409 )     (4,814 )             (2,960 )     (8,783 )
Non-operating gain (loss), net
    2       (444 )             123       (225 )
Loss before income taxes
    (1,407 )     (5,258 )             (2,837 )     (9,008 )
Provision for income taxes
    62       29               119       121  
Net Loss
  $ (1,469 )   $ (5,287 )           $ (2,956 )   $ (9,129 )
Net loss per share
  $ (0.06 )   $ (0.22 )           $ (0.12 )   $ (0.38 )
  $ (0.06 )   $ (0.22 )           $ (0.12 )   $ (0.38 )
Shares used in EPS (est of shares)
    24,356       24,244               24,282       24,178  
    24,356       24,244               24,282       24,178  


(in thousands, except per share data)

    December 31,
    2009   2008
Current assets:
Cash and cash equivalents
  $ 2,975     $ 11,235  
Accounts receivable, less allowance of $421 and $526 in 2009 and 2008, respectively
    4,229       3,758  
Inventory, net
    7,861       12,410  
Prepaid expenses and other current assets
    1,347       1,391  
Total current assets
    16,412       28,794  
Property, plant and equipment, net
    2,180       3,040  
Intangible assets, net
    472       613  
    2,926       2,926  
Deferred tax asset
    17       29  
Other assets
    170       306  
Total assets
  $ 22,177     $ 35,708  
Current liabilities:
Line of credit
  $     $ 5,404  
Accounts payable
    4,887       7,509  
Accrued liabilities
    5,600       8,255  
Deferred revenue, current portion
    1,123       2,603  
Total current liabilities
    11,610       23,771  
Deferred tax liabilities
    473       376  
Deferred revenue – long-term
    1,975       1,875  
Other liabilities – long-term
    190       296  
Total liabilities
    14,248       26,318  
Commitments and contingencies
Stockholders’ equity:
Preferred stock, par value $0.001; 1,000 shares authorized, no shares issued and outstanding
Common stock, par value $0.001; 50,000 shares authorized, 26,340 and 26,208 shares issued in 2009 and 2008, respectively; 24,376 shares and 24,244 shares outstanding in 2009 and 2008, respectively
    27       27  
Additional paid-in capital
    117,228       115,698  
Accumulated other comprehensive (loss)
    (222 )     (187 )
Accumulated deficit
    (92,705 )     (89,749 )
    24,328       25,789  
Treasury stock (cost of 1,964 shares repurchased)
    (16,399 )     (16,399 )
Total stockholders’ equity
    7,929       9,390  
Total liabilities and stockholders’ equity
  $ 22,177     $ 35,708  

Non-GAAP Financial Measures

The non-GAAP financial measures contained herein are a supplement to the corresponding financial measures prepared in accordance with generally accepted accounting principles (GAAP). The non-GAAP financial measures presented exclude the items summarized in the below table. Management believes that adjustments for these items assist investors in making comparisons of period-to-period operating results and that these items are not indicative of the Company’s on-going core operating performance.

Management uses non-GAAP net income (loss) and non-GAAP net income (loss) per diluted share in its evaluation of the Company’s core after-tax results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Management believes that providing these non-GAAP financial measures allows investors to view the Company’s financial results in the way that management views the financial results.

The non-GAAP financial measures presented herein have certain limitations in that they do not reflect all of the costs associated with the operations of the Company’s business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by the Company may be different from the non-GAAP financial measures used by other companies.


Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures
(in thousands, except per share data)

    Three months ended December 31,           Year ended December 31,
            2009   2008       2009               2008
GAAP net loss           $ (1,469 )   $ (5,287 )                   $ (2,956 )           $(9,129)
Interest Expense
            9       62                       58                       157  
Depreciation and Amortization Expense
    318       469                       1,444                       1,909  
Stock Based Compensation Expense
    254       419                       1,357                       1,735  
Non-GAAP net loss
    (888 )     (4,337 )                     (97 )           (5,328)
GAAP net loss per share:           $ (0.06 )   $ (0.22 )                   $ (0.12 )           $(0.38)
Basic and Diluted
Interest Expense
          $ 0.00     $ 0.00                     $ 0.00                     $ 0.01  
Depreciation and Amortization Expense
  $ 0.01     $ 0.02                     $ 0.06                     $ 0.08  
Stock Based Compensation Expense
  $ 0.01     $ 0.02                     $ 0.06                     $ 0.07  
Non-GAAP net loss per share:
Basic and Diluted
  $ (0.04 )   $ (0.18 )                   $ (0.00 )           $(0.22)

# # # #

The following information was filed by Biolase, Inc (BIOL) on Thursday, March 18, 2010 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Biolase, Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Biolase, Inc.


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019) Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019) Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account